DrugPatentWatch Database Preview
Glaxo Grp England Company Profile
What is the competitive landscape for GLAXO GRP ENGLAND, and when can generic versions of GLAXO GRP ENGLAND drugs launch?
GLAXO GRP ENGLAND has one approved drug.
There are ten US patents protecting GLAXO GRP ENGLAND drugs.
There are one hundred and forty-five patent family members on GLAXO GRP ENGLAND drugs in thirty-nine countries and fourteen supplementary protection certificates in eleven countries.
Summary for Glaxo Grp England
| International Patents: | 145 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Glaxo Grp England
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,201,556 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,746,242 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | 8,534,281 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Glaxo Grp England
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | 5,873,360 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for Glaxo Grp England Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| South Korea | 101037026 | ➤ Sign Up |
| Mexico | PA06009133 | ➤ Sign Up |
| Denmark | 1786498 | ➤ Sign Up |
| China | 101084030 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Glaxo Grp England Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1740177/03 | Switzerland | ➤ Sign Up | PRODUCT NAME: UMECLIDINIUM BROMID; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014 |
| 2014038 | Lithuania | ➤ Sign Up | PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428 |
| 565 | Luxembourg | ➤ Sign Up | PRODUCT NAME: BROMURE D'UMECLIDINUM; FIRST REGISTRATION DATE: 20140428 |
| 2014038,C1740177 | Lithuania | ➤ Sign Up | PRODUCT NAME: UMEKLIDINO BROMIDAS; REGISTRATION NO/DATE: EU/1/14/922 20140428 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
